{"id":168174,"date":"2023-07-23T21:54:13","date_gmt":"2023-07-24T02:54:13","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2023\/07\/5-sle-patients-see-disease-remission-with-car-t-cell-therapy"},"modified":"2023-07-23T21:54:13","modified_gmt":"2023-07-24T02:54:13","slug":"5-sle-patients-see-disease-remission-with-car-t-cell-therapy","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2023\/07\/5-sle-patients-see-disease-remission-with-car-t-cell-therapy","title":{"rendered":"5 SLE Patients See Disease Remission With CAR T-cell Therapy"},"content":{"rendered":"<p style=\"padding-right: 20px\"><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/5-sle-patients-see-disease-remission-with-car-t-cell-therapy2.jpg\"><\/a><\/p>\n<p>A CAR T-cell therapy targeting disease-driving immune cells safely led to sustained disease remission for five people with systemic lupus erythematosus (SLE) who\u2019d previously failed to respond to other treatments, a recent study reported.<\/p>\n<p>Treatment was also highly specific, preventing autoimmune activity, but didn\u2019t impair general immune system function.<\/p>\n<p>\u201cThese data provide new therapeutic possibilities to control SLE disease activity,\u201d the researchers wrote. \u201cLonger follow-ups in larger cohorts of patients will be necessary to confirm sustained absence of autoimmunity and resolution of inflammation in patients with SLE who have received CAR T cell therapy.\u201d<\/p>\n<p>Nature Abstract.<\/p>\n<p><a href=\"https:\/\/www.nature.com\/articles\/s41591-022-02017-5\">https:\/\/www.nature.com\/articles\/s41591-022-02017-5<\/a><\/p>\n<hr>\n<p>No systemic lupus erythematosus patient receiving the CAR T-cell therapy infusion relapsed, all remained in remission for up to 17 months.<\/p>\n<div class=\"more-link-wrapper\"> <a class=\"more-link\" href=\"https:\/\/lifeboat.com\/blog\/2023\/07\/5-sle-patients-see-disease-remission-with-car-t-cell-therapy\">Continue reading \u201c5 SLE Patients See Disease Remission With CAR T-cell Therapy\u201d | &gt;<\/a><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A CAR T-cell therapy targeting disease-driving immune cells safely led to sustained disease remission for five people with systemic lupus erythematosus (SLE) who\u2019d previously failed to respond to other treatments, a recent study reported. Treatment was also highly specific, preventing autoimmune activity, but didn\u2019t impair general immune system function. \u201cThese data provide new therapeutic possibilities [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-168174","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/168174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=168174"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/168174\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=168174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=168174"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=168174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}